Tech‘We’re not doing 30 bets a year’: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande, who left a16z’s roughly $4 billion biotech practice last year to launch the much smaller, AI-native VZVC, explains why biology is moving from discovery toward engineering. He also discusses the high cost of clinical trials and argues that open, shared datasets—not walled-off ones—will enable AI to transform medicine.

AIbiotechventure capital

TTechCrunch★★☆☆☆2026-08-29 17:36Original